Compare Booz Allen Hamilton Holding Corporation (BAH) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs BIO-TECHNE Corp — how do they compare? Booz Allen Hamilton Holding Corporation trades at $78.78 (market cap $9.37B), while BIO-TECHNE Corp trades at $72.19 (market cap $11.24B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and Booz Allen Hamilton Holding Corporation pays the higher dividend (3.03%). Which is the better fit depends on your goals.
| BAH | TECH | |
|---|---|---|
Market Cap | $9.37B | $11.24B |
Sector | Industrials | Health |
52-Week High | $111.63 | $72.29 |
52-Week Low | $59.71 | $43.31 |
Enterprise Value | $12.99B | $11.32B |
Dividend Yield | 3.03% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $76.05, up 2.87% with a bullish technical signal and strong earnings beats. Recent quarters show consistent EPS outperformance, with Q2 2026 actual EPS of $1.81 beating the $1.49 estimate. The stock benefits from a discounted valuation with a P/E of 11.94 and robust cash flow growth, though revenue declined 4.2% year-over-year in Q1 2027. National security demand remains a key driver, offset by civil segment weakness.
Outlook is cautiously positive with a consensus price target of $84.67, implying 11% upside. Strengths include high ROE of 68.11% and margin expansion, but risks involve elevated debt levels and revenue volatility. Investors should weigh valuation appeal against execution risks in government contracting.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
